Individualizing EoE Treatment Across the Age Spectrum

In this episode, ‘Individualizing EoE Treatment Across the Age Spectrum,’ the panelists explore how clinicians balance efficacy, safety, practical treatment demands, and patient preference when selecting therapy. The experts emphasize that even an effective treatment is unlikely to succeed if a patient cannot or will not use it consistently. They discuss tailoring treatment to disease severity and endoscopic findings while considering the feasibility of repeated dosing, dietary restrictions, self-injection, and access.

The conversation highlights the importance of understanding where patients are in life. A twice-daily regimen may be particularly challenging for younger adults, while other patients may be uncomfortable with injections or unable to sustain an elimination diet. Establishing trust allows patients to speak candidly about adherence and helps clinicians adapt therapy rather than judging incomplete use.

The faculty then focus on pediatric care and caregiver involvement. Treatment decisions for children require partnership with parents and other caregivers, who often administer therapy and recognize changes in symptoms. The panel reviews the EoE KIDS data with dupilumab, including histologic remission in younger children and maintenance of response through longer follow-up. Faculty also discuss improvements in endoscopic and histologic measures and the importance of achieving control early in children, who may otherwise live with active disease for decades. Growth findings are highlighted as another meaningful consideration when counseling families.

The next episode in this series, ‘Setting Expectations for Long-Term EoE Treatment,’ features the panelists discussing chronic therapy, reassessment, and practical access barriers that can alter the treatment plan.